The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 19, 2025

Filed:

Mar. 09, 2018
Applicant:

President and Fellows of Harvard College, Cambridge, MA (US);

Inventors:

Juan Pablo Maianti, Revere, MA (US);

David R. Liu, Lexington, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/50 (2006.01); A61K 31/7088 (2006.01); A61K 38/46 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 38/50 (2013.01); A61K 31/7088 (2013.01); A61K 38/465 (2013.01); A61K 39/0011 (2013.01); A61K 39/001106 (2018.08); A61K 39/00113 (2018.08); A61K 39/00115 (2018.08); A61K 39/001153 (2018.08); A61K 39/001156 (2018.08); A61K 39/001157 (2018.08); A61K 39/00117 (2018.08); A61K 39/001182 (2018.08); A61K 39/001188 (2018.08); A61K 39/001191 (2018.08); A61K 39/001192 (2018.08); A61K 45/06 (2013.01); A61K 39/001149 (2018.08); A61K 2039/5154 (2013.01); A61K 2039/53 (2013.01); A61K 2039/58 (2013.01); C07K 2319/00 (2013.01); C12Y 304/22062 (2013.01);
Abstract

Provided herein are systems, compositions, and methods for generating immunogenic peptides or epitopes from tumor associated antigens (e.g., in vivo or ex vivo). Polynucleotides (e.g., genes) encoding the tumor associated antigens may be edited at selected target sites by nucleobase editors comprising a catalytically-inactive Cas9 and a cytosine deaminase, leading to the expression of heteroclitic or cryptic peptides that are more immunogenic than the native peptide derived from the tumor associated antigens. The heteroclitic or cryptic peptide elicit strong tumor-specific immune response (e.g., T-cell response or B-cell response), which inhibits tumor growth and metastasis.


Find Patent Forward Citations

Loading…